Literature DB >> 29757486

Global status of diabetes prevention and prospects for action: A consensus statement.

Mahmoud Ibrahim1, Jaakko Tuomilehto2, Pablo Aschner3, Lucille Beseler4, Avivit Cahn5, Robert H Eckel6, Amy Hess Fischl7, George Guthrie8, James O Hill9, Mick Kumwenda10, R David Leslie11, Darin E Olson12, Paolo Pozzilli13,14, Sandra L Weber15, Guillermo E Umpierrez16.   

Abstract

Primary prevention of type 2 diabetes (T2D) should be achievable through the implementation of early and sustainable measures. Several randomized control studies that found success in preventing the progression to T2D in high-risk populations have identified early and intensive intervention based on an individualized prevention model as the key factor for participant benefit. The global prevalence of both overweight and obesity has now been widely recognized as the major epidemic of the 21st century. Obesity is a major risk factor for the progression from normal glucose tolerance to prediabetes and then to T2D. However, not all obese individuals will develop prediabetes or progress to diabetes. Intensive, multicomponent behavioural interventions for overweight and obese adults can lead to weight loss. Diabetes medications, including metformin, GLP-1 agonists, glitazones, and acarbose, can be considered for selected high-risk patients with prediabetes when lifestyle-based programmes are proven unsuccessful. Nutrition education is the cornerstone of a healthy lifestyle. Also, physical activity is an integral part of the prediabetes management plan and one of the main pillars in the prevention of diabetes. Mobile phones, used extensively worldwide, can facilitate communication between health professionals and the general population, and have been shown to be helpful in the prevention of T2D. Universal screening is needed. Noninvasive risk scores should be used in all countries, but they should be locally validated in all ethnic populations focusing on cultural differences around the world. Lifestyle interventions reduce the progression to prediabetes and diabetes. Nevertheless, many questions still need to be answered.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  diabetes prevention; obesity; prediabetes

Mesh:

Year:  2018        PMID: 29757486     DOI: 10.1002/dmrr.3021

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  10 in total

1.  Combined Dipeptidyl Peptidase 4 Inhibitor and α-Glucosidase Inhibitor Treatment in Postprandial Hypoglycemia.

Authors:  David T Broome; Alimitha Kodali; Danielle Phillips; Vinni Makin; Daniel Mendlovic; Robert S Zimmerman
Journal:  Clin Diabetes       Date:  2022-01

2.  Neutrophil extracellular traps promote macrophage inflammation and impair atherosclerosis resolution in diabetic mice.

Authors:  Tatjana Josefs; Tessa J Barrett; Emily J Brown; Alexandra Quezada; Xiaoyun Wu; Maud Voisin; Jaume Amengual; Edward A Fisher
Journal:  JCI Insight       Date:  2020-04-09

Review 3.  Efficacy of Low-Carbohydrate Ketogenic Diet in the Treatment of Type 2 Diabetes.

Authors:  Hussain M Dashti; Thazhumpal C Mathew; Naji S Al-Zaid
Journal:  Med Princ Pract       Date:  2020-10-09       Impact factor: 1.927

4.  Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice.

Authors:  Wei Wu; Liyun Liu; Hongrui Zhu; Yating Sun; Ying Wu; Hongze Liao; Yuhan Gui; Lei Li; Lei Liu; Fan Sun; Houwen Lin
Journal:  FASEB J       Date:  2019-08-26       Impact factor: 5.834

5.  Perceived diabetes risk and related determinants in individuals with high actual diabetes risk: results from a nationwide population-based survey.

Authors:  Christin Heidemann; Rebecca Paprott; Lena M Stühmann; Jens Baumert; Kristin Mühlenbruch; Sylvia Hansen; Catarina Schiborn; Daniela Zahn; Paul Gellert; Christa Scheidt-Nave
Journal:  BMJ Open Diabetes Res Care       Date:  2019-06-21

6.  Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study.

Authors:  Ayman A Al Hayek; Asirvatham A Robert; Mohamed A Al Dawish
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2019-03-18

7.  The Glucoamylase Inhibitor Acarbose Has a Diet-Dependent and Reversible Effect on the Murine Gut Microbiome.

Authors:  Nielson T Baxter; Nicholas A Lesniak; Hamide Sinani; Patrick D Schloss; Nicole M Koropatkin
Journal:  mSphere       Date:  2019-02-06       Impact factor: 4.389

8.  Hospitalization Costs of Lower Limb Ulcerations and Amputations in Patients with Diabetes in Romania.

Authors:  Diana I Sima; Cosmina I Bondor; Ioan A Vereşiu; Norina A Gâvan; Cristina M Borzan
Journal:  Int J Environ Res Public Health       Date:  2021-02-24       Impact factor: 3.390

9.  A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes.

Authors:  Yingying Luo; Hongyuan Wang; Xianghai Zhou; Cuiqing Chang; Wei Chen; Xiaohui Guo; Jinkui Yang; Linong Ji; Sanjoy K Paul
Journal:  J Diabetes Res       Date:  2022-01-06       Impact factor: 4.011

10.  Gene Cascade Shift and Pathway Enrichment in Rat Kidney Induced by Acarbose Through Comparative Analysis.

Authors:  Chun-Yue Weng; Mo-Han Zhu; Ke-Lei Dai; Zhe-Yan Mi; Yuan-Shan Wang; Zhi-Qiang Liu; Yu-Guo Zheng
Journal:  Front Bioeng Biotechnol       Date:  2021-05-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.